Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 15/20 | 0.44 |
| ▸ | PPARA | Q07869 | 9/20 | 0.44 |
| ▸ | PPARG | P37231 | 6/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24933849 | 0.87 | HSD17B1 (0.39) | PPARDPPARAPPARGFFAR1HSD17B1 | |
| SCHEMBL24933254 | 0.85 | HSD17B1 (0.38) | PPARDPPARAPPARGFFAR1HSD17B1 | |
| SCHEMBL24933002 | 0.84 | HSD17B1 (0.38) | HSD17B1HSD17B2 | |
| SCHEMBL24933706 | 0.83 | PARP10 (0.39) | PPARDPPARAPPARGHSD17B1HSD17B2 | |
| SCHEMBL24933809 | 0.83 | HSD17B1 (0.38) | PPARDHSD17B1HSD17B2 | |
| SCHEMBL24933881 | 0.81 | HSD17B1 (0.38) | PPARDHSD17B1HSD17B2 | |
| SCHEMBL24933639 | 0.81 | NMT1 (0.40) | FFAR1HSD17B1HSD17B2 | |
| SCHEMBL30240787 | 0.81 | HSD17B1 (0.38) | PPARDHSD17B1HSD17B2 | |
| SCHEMBL24933369 | 0.81 | HSD17B1 (0.38) | PPARDHSD17B1HSD17B2 | |
| SCHEMBL30240751 | 0.80 | HSD17B1 (0.41) | HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |